Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Allergic contact dermatitis caused by dipropylene glycol diacrylate in the Omnipod® insulin pump

Ulriksdotter, J. LU orcid ; Svedman, C. LU ; Bruze, M. LU and Mowitz, M. LU (2022) In British Journal of Dermatology 186(2). p.334-340
Abstract

Background: Cases of allergic contact dermatitis (ACD) caused by isobornyl acrylate (IBOA) in the Omnipod® insulin pump have previously been reported. Objectives: To present three cases of patients with ACD caused by a new allergen in the pump, and results from chemical analyses. Methods: Omnipod pumps from different batches were analysed by gas chromatography–mass spectrometry. Aimed testing, with the department’s medical device (MD) series and substances identified in the pump including dipropylene glycol diacrylate (DPGDA) at 0·01% and 0·1% in petrolatum (pet.), was performed. Patch testing also included extracts from the device, the adhesive patch as is, and allergens from baseline series. Results: All patients tested positive to... (More)

Background: Cases of allergic contact dermatitis (ACD) caused by isobornyl acrylate (IBOA) in the Omnipod® insulin pump have previously been reported. Objectives: To present three cases of patients with ACD caused by a new allergen in the pump, and results from chemical analyses. Methods: Omnipod pumps from different batches were analysed by gas chromatography–mass spectrometry. Aimed testing, with the department’s medical device (MD) series and substances identified in the pump including dipropylene glycol diacrylate (DPGDA) at 0·01% and 0·1% in petrolatum (pet.), was performed. Patch testing also included extracts from the device, the adhesive patch as is, and allergens from baseline series. Results: All patients tested positive to 0·1% DPGDA in pet., and two patients additionally to a 0·01% concentration. DPGDA was found in extracts of the Omnipod pumps brought by the patients. An Omnipod pump from an earlier batch contained tripropylene glycol diacrylate, IBOA, N,N-dimethylacrylamide, di(ethylene glycol)ethyl ether acrylate (DEGEA) but no DPGDA. One of the patients reacted positively to all of these allergens except DEGEA, which was not tested. Conclusions: When suspecting ACD to MDs, DPGDA at 0·1% in pet. should be tested. The contents of Omnipod have changed over time. Patch testing with updated test series and relevance assessment of positive reactions is a delicate task. Children, with lifelong use of MDs, risk contracting many allergies with potential cross-allergies. A question should be raised as to whether these low molecular weight acrylates should be used at all in devices constantly worn on the skin.

(Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
British Journal of Dermatology
volume
186
issue
2
pages
334 - 340
publisher
Wiley-Blackwell
external identifiers
  • pmid:34510410
  • scopus:85118432711
ISSN
0007-0963
DOI
10.1111/bjd.20751
language
English
LU publication?
yes
additional info
Publisher Copyright: © 2021 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
id
98e3a51d-2eed-4654-b09c-510ce41fb4f0
date added to LUP
2021-12-02 12:48:47
date last changed
2024-06-15 21:51:05
@article{98e3a51d-2eed-4654-b09c-510ce41fb4f0,
  abstract     = {{<p>Background: Cases of allergic contact dermatitis (ACD) caused by isobornyl acrylate (IBOA) in the Omnipod® insulin pump have previously been reported. Objectives: To present three cases of patients with ACD caused by a new allergen in the pump, and results from chemical analyses. Methods: Omnipod pumps from different batches were analysed by gas chromatography–mass spectrometry. Aimed testing, with the department’s medical device (MD) series and substances identified in the pump including dipropylene glycol diacrylate (DPGDA) at 0·01% and 0·1% in petrolatum (pet.), was performed. Patch testing also included extracts from the device, the adhesive patch as is, and allergens from baseline series. Results: All patients tested positive to 0·1% DPGDA in pet., and two patients additionally to a 0·01% concentration. DPGDA was found in extracts of the Omnipod pumps brought by the patients. An Omnipod pump from an earlier batch contained tripropylene glycol diacrylate, IBOA, N,N-dimethylacrylamide, di(ethylene glycol)ethyl ether acrylate (DEGEA) but no DPGDA. One of the patients reacted positively to all of these allergens except DEGEA, which was not tested. Conclusions: When suspecting ACD to MDs, DPGDA at 0·1% in pet. should be tested. The contents of Omnipod have changed over time. Patch testing with updated test series and relevance assessment of positive reactions is a delicate task. Children, with lifelong use of MDs, risk contracting many allergies with potential cross-allergies. A question should be raised as to whether these low molecular weight acrylates should be used at all in devices constantly worn on the skin.</p>}},
  author       = {{Ulriksdotter, J. and Svedman, C. and Bruze, M. and Mowitz, M.}},
  issn         = {{0007-0963}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{334--340}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{British Journal of Dermatology}},
  title        = {{Allergic contact dermatitis caused by dipropylene glycol diacrylate in the Omnipod® insulin pump}},
  url          = {{http://dx.doi.org/10.1111/bjd.20751}},
  doi          = {{10.1111/bjd.20751}},
  volume       = {{186}},
  year         = {{2022}},
}